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Targeting T cells alone has yielded limited success in the
prevention of graft versus host disease (GvHD) after allogeneic
blood and marrow transplantation (BMT). Dendritic cells
(DCs) play a central role in alloreactivity and therefore
represent a suitable target. Due to their immune modulatory
effects and their inhibition of maturation and function of DC,
proteasome inhibitors have prompted investigators to
examine their potential role in the prevention of GvHD. Ixa-
zomib is a speciﬁc and reversible proteasome inhibitor with
rapid dissociation from 20S proteasome. It is orally bioavail-
able. We aimed to explore its effect on healthy volunteer DCs.
DCs were isolated using EasySep Pan-DC Pre-Enrichment
Cocktail with a purity over 90% (STEMCELL Technologies). DCs
were treated with ixazomib at different concentrations for 4
hrs and then stimulated with Lipopolysaccharide (LPS) for 16
hrs. After the treatment, DCs were surface stained with anti-
bodies against maturation markers and analyzed by ﬂow
cytometry. DC survival was evaluated with 7AAD staining and
FACS analysis. To assess the effect of ixazomib on the pro-
duction of pro-inﬂammatory cytokines, DCs were incubated
with ixazomib at increasing concentration before or after
addition of LPS. Pro-inﬂammatory cytokines in the superna-
tant of tissue culture were measured using EMD Millipore
cytokine arrays. Experiments were done in triplicate at least.
Unpaired T test was used for statistical analysis. P < 0.05 was
considered signiﬁcant.
Ixazomib inhibited expression of 6 DCmaturation markers
including CD40, CD54, CD80, CD83, CD86 and CD197 (CCR-7).
The inhibition started at a concentration of 10 nM and was
dose related. Ixazomib also decreased the percentage of DCs
simultaneously expressing multiple markers. DCs viability
remained unchanged in comparison to control at a concen-
tration of 10 nM and dropped to 68% and 43% on average with
concentrations of 20 nM and 40 nM. There was no signiﬁcant
change in the cytokine production when ixazomib was added
4 hours after LPS. On the other hand, ixazomib signiﬁcantly
decreased production of IL-6 and IL-23 by DCs at the con-
centration of 20-30 nM. However, there was no signiﬁcant
change of TNF-b and INF-g upon ixazomib treatments.
In summary, ixazomib inhibits DC maturation with rela-
tive preservation of cell viability. On the other hand, ixazo-
mib inhibits pro-inﬂammatory cytokine production in DCs
only when it is added before LPS stimulation. This may have
clinical implications and suggests that adequate inhibition of
DCs before graft infusion might be essential to the preven-
tion GvHD.466
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Improved prevention of graft versus host disease (GvHD)
without impairing graft versus disease (GvD) effect is para-
mount to the progress of allogeneic blood and marrow
transplantation. Both cyclophosphamide (Cy) and bortezo-
mib (Bor) selectively destroy rapidly proliferating recipient-
reactive T cells and may represent a step in the right direc-
tion. Post-transplant Cy (PTCy) also induces sustained toler-
ance by intrathymic depletion of donor T cells while
enhancing regulatory T cell expansion. Bor also impairs
dendritic cells maturation and function. Herein, we provide
updated results to a phase I study combining PTCy & Bor for
the prevention of GvHD after sibling or unrelated matched
donor peripheral blood stem cell transplantation.
Fifteen patients with median age of 56 (37-66) were
enrolled; 5 patients had AML, 4 MDS, 3 CLL, 1 follicular lym-
phoma, 1 MM, and 1 DLBCL. Disease risk index was high in 6,
intermediate in 4, and low in 5 patients. Patients received
reduced-intensity conditioningwithﬂudarabine and busulfan.
rATG was also given (range 5-8 mg/kg) to patients receiving
graft fromunrelateddonor (n¼8). Twodoses of Borwere given
IV, 6 hrs after transplant and 72 hrs thereafter. Three patients
were enrolled in each of cohorts 1 and 2 and 9 in cohort 3. The
dose of Bor in the 3 cohorts was 0.7, 1, and 1.3 mg/m2 respec-
tively. Cy 50 mg/kg IV was given on days 3 and 4 post-trans-
plant. Themedian time to neutrophil engraftmentwas 16 days
(13-23). One patient required prolonged foscarnet course and
died on day 150 without achieving platelet engraftment. For
the remaining 14 patientsmedian time to platelet engraftment
was 28 days (15-104). Fourteen patients had full chimerism by
day21. The remainingpatienthad residual CLL and reached full
chimerism by day 118. There was no secondary graft failure.
Besides anticipated hematological toxicity, no other grade 3 or
4 occurred. Two patients (13%) died due to treatment on day
150 (RSV pneumonitis) and 200 (acute sepsis). Two patients
enrolled early in the study developed extensive HSV genito-
rectal ulcers. No other cases were encountered when the
institutional practice changed to start acyclovir on the ﬁrst day
of conditioning insteadofday5.CMVreactivationoccurred in8
patients. One patient developed BK virus-induced hematuria
and1CNStoxoplasmosis.Withmedian follow-upof11months
(1-30), the predicted DFS and OS at 2 years were 62% and 66%
respectively. The incidence of grade II-IV and III-IV acute GvHD
in the14evaluablepatientswas14%and7%respectively.Only1
patient developed visceral GvHD. Three out of 11 patientswith
follow-up > 6 months developed chronic GvHD (27%).
In sum, PTCy & Bor for GvHD prophylaxis is feasible and
permits prompt engraftment. Albeit small, our study sug-
gests low incidence of signiﬁcant acute GvHD, in particular,
visceral. The combination is also attractive by its conve-
nience. The study has been extended to a phase II.467
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